Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Priori Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel management NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside …
Sharemaestro market context Trend signal active 52 weeks +38.5%Pfizer CEO Albert Bourla recently purchased $1 million worth of company stock, acquiring 38,000 shares at $26.34 each. This insider buying signals confidence in Pfizer's future, particularly as the company aims to convince investors about improving operational trends and its medication pipeline. While the …
Sanofi and UNICEF have partnered to improve childhood immunisation access in three Eastern Cape districts in South Africa, targeting children who have not received or completed routine vaccinations. The "Immunisation for Every Child" program, running from July 2026 to March 2027, will equip health …
Daiwa Securities has increased its price target for Amgen (AMGN) from $390 to $430, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the firm regarding the biotechnology group. The article also lists other recent analyst adjustments for …
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, …
Sharemaestro market context Trend signal active 52 weeks +57.8%MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) …
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: …
Barclays has adjusted its price target for Amgen (AMGN) to $380, an increase from the previous $360, while maintaining an Equalweight rating on the stock. This update reflects Barclays' ongoing assessment of the biotechnology company's valuation. The article also notes recent adjustments by other …
Wolfe Research has upgraded Biogen (BIIB) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a positive outlook from the firm regarding Biogen's future stock performance. The report was published on August 13, 2026, at 07:40 …
Wolfe has upgraded AbbVie (ABBV) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a more positive outlook on the pharmaceutical company's stock performance. The article also lists recent news and analyst actions related to AbbVie, …
Novo Nordisk CEO Mike Doustdar stated his belief that the obesity drug market, particularly for GLP-1s, will not be a winner-takes-all scenario. He anticipates that consumers will continue to seek various options for weight loss. This outlook suggests a competitive landscape rather than a …
Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and its acquisition MyoKardia. The suit aims to prevent a potential patent infringement case concerning Cytokinetics' heart disease treatment, Myqorzo (aficamten). The dispute involves U.S. Patent No. 12,616,697.
Mission Wealth Management LP significantly increased its stake in Novartis AG (NYSE:NVS) during the second quarter, purchasing an additional 9,086 shares to bring its total holdings to 19,690 shares valued at approximately $3.09 million. Other institutional investors also expanded their positions, though hedge funds …
SOA Wealth Advisors LLC. significantly increased its stake in Novartis AG (NYSE:NVS) by 4,316.2% in the second quarter, acquiring 14,416 additional shares to reach a total of 14,750 shares valued at $2.31 million. Other institutional investors also adjusted their positions in Novartis, with institutions …
Mission Wealth Management LP significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, now holding 69,052 shares valued at $17.4 million. This move is part of a broader trend of institutional investors and hedge funds holding 70.23% of AbbVie's …
Prevail Innovative Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 45.0% during the second quarter, bringing its total holdings to 29,458 shares valued at $3,785,000. Several other institutional investors also adjusted their positions in MRK, contributing to a total institutional …
(Bloomberg) -- As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world's safest firms. Most Read from Bloomberg Walter Sells Lakers, Seeks More …
Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets …
Wealthcare Advisory Partners LLC acquired 12,112 shares of AstraZeneca Plc, valued at approximately $2.3 million, in the second quarter. This move is part of a broader trend of institutional investors increasing their holdings in the pharmaceutical company, which now has 20.35% institutional ownership. AstraZeneca …
Handelsbanken Fonder AB increased its stake in Biogen Inc. (NASDAQ:BIIB) by 12.7% during the second quarter, bringing its total holdings to 93,236 shares valued at $20.14 million. Institutional investors collectively own 87.93% of Biogen, which has received a consensus "Moderate Buy" rating from analysts …
[Doctor with vial of the doses vaccine for MMR Measless, Mumps and Rubella diseases. Medicine and health care concept] angelp/iStock via Getty Images President Donald Trump's executive order aimed at splitting the combined measles, mumps and rubella (MMR) vaccine faces a major hurdle – …
Sharemaestro market context Trend signal active 52 weeks +57.8%Sei Investments Co. significantly increased its stake in Organon & Co. by 82% in the first quarter, now holding 190,057 shares valued at approximately $1.14 million. Organon's shares have shown strong performance, trading near their 52-week high, and the company recently declared a quarterly …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …
Company Logo Rapid commercial maturity across the country's industrial and enterprise sectors highlighted by NTT DATA's recognition as a 2026 Leader in private mobile networks, Fujitsu's expanding subscription-based Local 5G models, and NEC's Open RAN smart factory deployments is accelerating dedicated private spectrum adoption …
The average 12-month price target for Pfizer, Inc. (PFE) stock has been reduced from $28.47 to $28.28 by 24 analysts, with forecasts ranging from $25 to $35.75. This updated target implies a potential upside of approximately 7% from the Aug. 12 closing price. The …
Amgen (AMGN) is experiencing renewed interest after strong Q2 2026 results and raised full-year guidance, leading to a significant jump in share price. While one valuation model suggests the stock is 15.6% overvalued at $416.18, another Discounted Cash Flow (DCF) model estimates it as …
This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration …
VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …
Search by ticker symbol or company name and select a result to open its chart.